Skip to content

Acri.LISA® bifocal intraocular lens (Carl Zeiss UK) versus AcrySof® IQ ReSTOR® multifocal intraocular lens

Evaluation of post-operative dysphotopsia and spectacles independence after bilateral multifocal intraocular lens (IOL) implantation for cataract surgery and refractive lens exchange: Acri.LISA® 366D versus AcrySof® SN6AD1 randomised clinical trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN64155646
Enrollment
188
Registered
2010-09-06
Start date
2010-09-01
Completion date
Unknown
Last updated
2016-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cataracts Eye Diseases Other cataract

Interventions

We plan to randomise patients who have no significant ocular copathology, and are undergoing bilateral sequential cataract surgery or bilateral sequential refractive lens exchanged to either bilateral

Sponsors

Moorfields Eye Hospital NHS Foundation Trust (UK)
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Patients undergoing sequential bilateral cataract surgery or refractive lens exchange 2. Patients that want to be spectacle independent 3. Male or female, aged 21 years and above

Exclusion criteria

Exclusion criteria: 1. Any significant ocular co-morbidity (amblyopia, age-related macular degeneration [ARMD], glaucoma, etc) precluding post-operative visual acuity (VA) of 20/30 or better or poor zonular/capsular stability (e.g. after trauma/severe pseudoxanthoma elasticum [PXE]) 2. Corneal astigmatism more than 1.50 D on IOLMaster keratometry. Corneal astigmatism between 1.00 - 1.50 D will be reduced using standardised limbal relaxing incisions (LRI). 3. IOLMaster biometry not possible 4. IOL power less than 10D or greater than 30D 5. Professional night drivers, pilots, and other occupations for which induced dysphotopsia may be career threatening 6. Patients with severe psychiatric disorders 7. Vulnerable groups 8. Poor mobility 9. Poor comprehension of written English

Design outcomes

Primary

MeasureTime frame
The presence of dysphotopsia symptoms (absent, mild, moderate, severe). Dysphotopsia (glare/haloes/visual disturbances) will be assessed with a questionnaire. Primary and secondary outcomes to be measured 4 - 6 months post-operatively.

Secondary

MeasureTime frame
1. Autorefraction and aberrometry and pupil size measurement using the Tracey aberrometer 2. Manifest subjective refraction and spectacle corrected monocular visual acuity measurement 3. Composite scoring of unaided visual acuity; distance and near monocular photopic. Binocular photopic distance, intermediate (50 - 60 - 70 cm) and near (40 cm) visual acuity. Binocular mesopic intermediate (70 cm), distance and near (using neutral density filters NoirU23). The composite scoring system is to be developed during the trial. Visual acuities will be measured using the New ETDRS logarithmic acuity card (Precision Vision). 4. Maximum binocular reading speed at patient preferred distance (IReST) 5. Binocular Near Reading speed 6. Binocular Contrast sensitivity - Pelli-Robson under photopic/mesopic conditions 7. Forward light scatter (C-quant) 8. Spectacle dependence questionnaire 9. Visual satisfaction questionnaire 10. Quality-of-life questionnaire (QIRC score) 11. Visual disability questionnaire - Catquest-9SF patient outcome questionnaire 12. Intra and postoperative complications 13. Slit lamp findings (dilated pupil): IOL centration 14. Adverse event recording (email and CRF) Primary and secondary outcomes to be measured 4 - 6 months post-operatively.

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026